Furthermore, metformin, which is a YAP inhibitor, was able to significantly reduce CS formation and progression in vivo in the double Trp53/Rb1 knockout model, thus indicating YAP inhibition as a potential therapeutic strategy for CS [22]. Here, RB1 is linked to Cowden syndrome 1.